[The best evidence for the management of ovarian hyper-stimulation syndrome in patients undergoing assisted reproductive therapy].

Objectives: To summarize the best evidence for the management of ovarian hyperstimulation syndrome in patients undergoing assisted reproductive therapy.

Methods: Evidence related to the management of ovarian hyperstimulation syndrome in patients undergoing assisted reproductive therapy, including guidelines, clinical decision, best clinical practice, systematic evaluation, expert consensus and evidence summary and related original research were systematically searched in UpToDate, BMJ Best Practice, World Health Organization (WHO) website, Guidelines International Network (GIN), National Institute for Health and Clinical Excellence (NICE) website, National Guidelines website, American Society for Reproductive Medicine (ASRM) website, New York Academy of Sciences (NYAS) website, Joanna Briggs Institute (JBI) database, Cochrane Library, CINAHL, PubMed, Wanfang database, CNKI, and China Biomedical Literature Database from inception to May 31, 2024. Two researchers independently evaluated the quality of the literature, and a senior researcher made the final decision for literature inclusion.

Results: A total of 15 articles were included in the study. Following quality assessment, one article was excluded. The remaining 14 articles included 5 practice guidelines, 3 systematic reviews, 2 expert consensuses, 1 evidence summary, and 3 from UpToDate. Ultimately, 27 pieces of evidence were identified across five key aspects: risk assessment, disease monitoring, early prevention, institutional management and health education.

Conclusions: The updated evidence indicates that the monitoring and prevention of ovarian hyperstimulation syndrome should start early, personalized treatment plans should be provided for patients, and the rational allocation of treatment resources needs to be promoted to enhance effective management of ovarian hyper-stimulation syndrome.